CryoLife finds FibRx development partner:
This article was originally published in Clinica
Executive Summary
Bayer (Germany) has paid CryoLife $250,000 for exclusive rights to negotiate the terms and conditions of a worldwide licence for CryoLife's patented fibrin-based bioadhesive, FibRx. The agreement provides Bayer with a six month review period and, if a licence is granted, the companies will develop the product together in the US (see Clinica No 693, p 15). Bayer will be responsible for development of the product in rest of the world. Provided both agree to the terms, CryoLife may receive development and milestone payments up to $25 million.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.